Document Detail


Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
MedLine Citation:
PMID:  23407557     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: ALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma kinase (ALK) overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the standard procedure for detection of ALK rearrangements in lung ACA but requires specialized equipment and expertise. Immunohistochemistry (IHC) for ALK protein overexpression is a promising screening modality, with reports of newer antibodies showing excellent sensitivity and specificity for ALK-rearranged lung ACA.
METHODS: In this study, we analyzed ALK IHC (5A4 clone) in 186 cases from our clinical service and compared it with ALK FISH and EGFR and KRAS mutation status.
RESULTS: Twelve cases had concordant ALK protein overexpression and ALK rearrangement by FISH. Three ALK-rearranged cases lacked ALK protein expression. Of these discrepant cases, one had a coexisting EGFR mutation and a subtle atypical ALK rearrangement manifested as a break in the 5' centromeric portion of the FISH probe. One case had a concurrent BRAF mutation. Follow-up testing on a metastasis revealed absence of the ALK rearrangement, with persistent BRAF mutation. In one ALK-rearranged protein negative case, very limited tissue remained for ALK IHC, raising the possibility of false negativity because of protein expression heterogeneity. Importantly, ALK protein expression was detected in one case initially thought not to have an ALK rearrangement. In this case, FISH was falsely negative because of interference by benign reactive nuclei. After correcting for these cases, ALK IHC was 93% sensitive and 100% specific as compared with FISH.
CONCLUSIONS: ALK IHC improves the detection of ALK rearrangements when used together with FISH, and its use in lung ACA genetic testing algorithms should be considered.
Authors:
Lynette M Sholl; Stanislawa Weremowicz; Stacy W Gray; Kwok-Kin Wong; Lucian R Chirieac; Neal I Lindeman; Jason L Hornick
Related Documents :
4006897 - Considerations on the significance attributed to unusual cerebral histological findings...
15377317 - Trigeminal autonomic cephalgias and variants: clinical profile in indian patients.
1719137 - Intractable seizures from infancy can be associated with dentato-olivary dysplasia.
16622567 - Generalized periodic eeg activity in two cases of neurosyphilis.
2071547 - Coronary collateral flow reversal.
22088257 - Benign paroxysmal positional vertigo showing sequential translations of four types of n...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  8     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-14     Completed Date:  2013-07-30     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  322-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / diagnosis*,  genetics,  metabolism
Aged
Algorithms
Female
Follow-Up Studies
Gene Rearrangement*
Genetic Testing
Humans
Immunoenzyme Techniques
In Situ Hybridization, Fluorescence*
Lung Neoplasms / diagnosis*,  genetics,  metabolism
Male
Middle Aged
Mutation / genetics
Neoplasm Staging
Prognosis
Proto-Oncogene Proteins / genetics
Receptor Protein-Tyrosine Kinases / genetics*,  metabolism*
Receptor, Epidermal Growth Factor / genetics
Sensitivity and Specificity
Survival Rate
Tumor Markers, Biological / genetics
ras Proteins / genetics
Grant Support
ID/Acronym/Agency:
P50 CA090578/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/KRAS protein, human; 0/Proto-Oncogene Proteins; 0/Tumor Markers, Biological; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/Receptor Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/anaplastic lymphoma kinase; EC 3.6.5.2/ras Proteins
Comments/Corrections
Comment In:
J Thorac Oncol. 2014 Feb;9(2):e18-9   [PMID:  24419430 ]
J Thorac Oncol. 2013 Mar;8(3):255-6   [PMID:  23407554 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with ...
Next Document:  Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-...